HLA-C and neoplasm: Given that most targetable, MHC and non-MHC presented antigens are not “tumor-private” antigens but are shared with non-malignant counterparts, i.e. the cells-of-origin, differential antigen density might be exploited to increase tumor-cell-directed specificity [51].